Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | FGFR3 |
| Variant | positive |
| Impact List | unknown |
| Protein Effect | unknown |
| Gene Variant Descriptions | FGFR3 positive indicates the presence of FGFR3 mRNA and/or protein. |
| Associated Drug Resistance | |
| Category Variants Paths |
FGFR3 positive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR3 positive | head and neck squamous cell carcinoma | predicted - sensitive | Rogaratinib | Case Reports/Case Series | Actionable | In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including a partial response in a patient with FGFR3-positive head and neck squamous cell carcinoma (PMID: 31405822; NCT01976741). | 31405822 |
| FGFR3 positive | lung adenocarcinoma | predicted - sensitive | Rogaratinib | Case Reports/Case Series | Actionable | In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR3-positive lung adenocarcinoma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741). | detail... |
| FGFR3 positive | stomach cancer | predicted - sensitive | Rogaratinib | Case Reports/Case Series | Actionable | In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR3-positive gastric cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741). | detail... |
| FGFR3 positive | lung squamous cell carcinoma | predicted - sensitive | Rogaratinib | Case Reports/Case Series | Actionable | In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR3-positive lung squamous cell carcinoma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741). | detail... |